Navigation Links
AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease
Date:7/8/2009

veloping proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

About Gaia BioPharma

Gaia BioPharma Limited, a privately held, early stage biopharmaceutical company focused on hospital-based injectable therapeutics. Gaia BioPharma seeks to address key unmet therapeutic needs by taking established compounds and changing their administration routes to create patent-protected, value-added products.

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
2. AlphaRx Shareholder Update
3. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
4. AlphaRx Signs Cooperative Research and Development Agreement with US Army
5. AlphaRx Provides Corporate and Development Update
6. AlphaRxs Indaflex(TM) Continues its Clinical Development
7. AlphaRx CEO Accumulates More Company Shares
8. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
9. AlphaRx Announces Debt Conversion
10. AlphaRx To Present at 47th Annual ICAAC
11. Recent News Reports of Sweetener Reformulations Raise Questions About Motivations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 05, 2015 Buckeye Health Plan ... new CEO and plan president of Buckeye Health Plan. ... the position immediately. , Hill has more than 28 ... the Pacific Northwest, from managed care to large health ... and CEO of HealthPlus of Michigan, a health plan ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Igantia ... San Francisco, leads an international initiative to examine key ... extend the human lifespan. Scientists at Igantia believe ... women, from the initiation of her menstrual cycle to ... mechanism for aging and, ultimately, extend the lifespan. ...
(Date:5/5/2015)... 2015 HealthSlide, Inc ., ... solutions for hospitals nationwide, has announced the launch ... CIOs and CTOs can access the calculator on ... both initial and ongoing savings of switching to ... nation’s hospitals pay an average of $300,000 a ...
(Date:5/5/2015)... 05, 2015 After record-breaking sales of ... 2014, Walgreens introduces the Cookies & Cream flavor at ... Extend Nutrition has continually raised the bar for nutritional ... combined with an unprecedented nutritional profile, backed by international ... Extend Nutrition will launch additional new products and expand ...
(Date:5/5/2015)... May 05, 2015 Every year, news articles ... Turns out, the worst dry eye season is spring, also ... in most of the United States. The only season offering ... advocate Sharon Kleyne, host of the Sharon Kleyne Hour™ Power ... her radio show of May 11, 2015. Kleyne is the ...
Breaking Medicine News(10 mins):Health News:Buckeye Health Plan Announces New Chief Executive Officer 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 3Health News:Igantia Announces Digital Initiative to Decode Longevity 2Health News:HealthSlide Launches ROI Cost Calculator 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 4Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3
... According to findings of a recent study researchers say bypass ... for many patients // with blocked heart arteries . ... on-pump (work of the heart is shifted to a mechanical ... still beating) surgery. Results of the surgeries were evaluated one ...
... in addition to medication show an improved clinical recovery ... to a new study. ,Researchers examined 126 patients ... in the middle cerebral artery. All the patients were ... of symptom onset. 63 patients were randomly assigned to ...
... cardiovascular disease risk factors, which include high blood pressure, impaired ... the condition is made if you have three out of ... risk for cardiovascular disease. According to a new study, starting ... add extra risk. ,Based on findings of the study ...
... and one of the most frequent causes of indigestion. Typical ... cases. Smoking and a high salt intake significantly increase the ... study. ,Results of the study showed that people ... 70-percent more likely to have acid reflux than non-smokers. Those ...
... more over several years puts one at greater risk for heart ... weight . ,Researchers studied nearly 2,500 adults between ages ... or more during the study, and 20 percent of these people ... and diabetes. But only 4 percent of those who didn't gain ...
... new study shows that not being in optimum cardiovascular health ... say researchers .// ,Researchers say they have found ... cognitive impairment in the elderly. The conditions of metabolic syndrome ... blood glucose levels, high blood pressure, and low levels of ...
Cached Medicine News:
(Date:5/5/2015)... 5, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... randomized, double-blinded, placebo-controlled Phase 2 clinical trial of ... in combination with nab-paclitaxel and gemcitabine, versus nab-paclitaxel ... pancreatic cancer who have high serum levels of ... fourth leading cause of cancer death in ...
(Date:5/5/2015)... May 5, 2015   Cynosure, Inc. (Nasdaq: ... devices for aesthetic procedures and precision surgical applications worldwide, ... March 31, 2015. First-Quarter Highlights: , ... , Non-GAAP earnings of $0.15 per share; GAAP earnings ... at March 31, 2015 "Cynosure delivered 21 ...
(Date:5/5/2015)... 5, 2015  Astellas announced that two abstracts detailing ... detailing clinical data from a study of mirabegron as ... a late breaking plenary session at the 2015 annual ... 17 in New Orleans, Louisiana . ... studies designed to evaluate enzalutamide compared to bicalutamide in ...
Breaking Medicine Technology:Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 2Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 3Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 2Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 3Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 5Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 6Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 7Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 8Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 9Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 10Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 11Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 2Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 3Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 4Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 5Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 6Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 7Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 8Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 9
... Inc. (Nasdaq: TNGN ), a leader in ... clinical assessment of the first implanted bladder cancer patient ... expected and has permitted the second patient to be ... trial calls for each of the first few patient ...
... A new white paper urges medical device and ... validation program as a means of preventing the ... terminally sterilized medical products are based on years of ... of failures occur due to inadequate package validation programs," ...
Cached Medicine Technology:Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients 2Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients 3New White Paper: Having a Solid Package Validation Program Can Prevent Failure of Combination Products 2New White Paper: Having a Solid Package Validation Program Can Prevent Failure of Combination Products 3
Legionella IgG/M ELISA....
Measles IgM ELISA....
... The Wampole EBV ELISA test ... of assays for the determination ... tests for Viral Capsid Antigen ... Nuclear Antigen (EBNA). Most Wampole ...
Toxo IgG ELISA. All Wampole ELISA kits include the following: 12 x 8 well strips with breakaway wells, sample diluent, controls and calibrators, conjugate, TMB substrate, wash buffer, stop solution,...
Medicine Products: